NCCN just released new Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric Cancer Guidelines (Version 1.2026) on June 16th, 2026!
For Lynch Syndrome-associated cancers, genetic testing recommended for:
- All colorectal and endometrial cancers
- All ovarian and pancreatic cancers (per NCCN BOPP guidelines)
For all other Lynch-associated cancers, tumor screening for MMR deficiency recommended regardless of age at diagnosis, including:
- sebaceous neoplasms
- small bowel
- biliary tract
- brain
- bladder/urothelial
- adrenocortical cancers
Reference: Latham A, et al. J Clin Oncol 2019;37(4):286-295. PMID: 30376427.
To read the referenced article visit: https://pmc.ncbi.nlm.nih.gov/articles/PMC6553803/
To access these new guidelines, create a free account at NCCN.org and visit the following link: https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceeg.pdf
Through ICARE, we aspire to share cancer-related information that may be of interest. If you have questions or clarifications, please direct them to your healthcare provider.
